Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG/PK/PD study of irinotecan and its application in the treatment of malignant tumors
ChiCTR2500111380Phase 4Not yet recruiting
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan in colorectal cancer (CRC) and bronchial carcinoma, sponsored by Yan'an Affiliated Hospital of Kunming Medical University. Primary endpoint: blood drug concentration. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2500111380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111380.